In summary, our present study demonstrated that abnormal expression of METTL3 could serve as an important prognostic predictor for ccRCC patients, and we also indicated a novel regulatory mechanism of HHLA2 by mRNA epigenetic modification via METTL3. This evidence concerns the gene HHLA2 and nonpapillary renal cell carcinoma.